62 FORMULATING FOR MILDNESS
l Filaggrin (FLG) abundance In AS, FLG abundance decreases by more than 50%. Topic applications of different concentrations of the new active increase FLG abundance in AS (Fig 7). Eventually, the use of 5% of the new active
increases by 79% the FLG presence in inflamed skin.
The new active re-establishes skin health
restoring a normal barrier and increasing moisture retention.
The analysis by immunofluorescence
confirms these results as illustrated in Figure 8: healthy and hydrated skin are characterised by high levels of FLG (with an intense green fluorescence as indicated by the circle on control untreated image). In AS, we see a decrease of FLG. As we see in Figure 8, green
fluorescence increases with the new active at 3% and 5%. The new active increases FLG levels in atopic skin and thereby helps to restore hydration & water retention.
l Involucrin (INV) abundance In AS, INV abundance decreases by more than 60%. Topic applications of different concentrations of the new active increases INV abundance in AS (Fig 9). Eventually, the use of 5% of the new active increases by 169% the INV presence in inflamed skin and allows to inhibit the inflammation damage recovering a normal healthy skin regarding INV levels. The new active re-establishes skin health re-building a strong barrier and re-
PERSONAL CARE EUROPE
structuring the cornified envelope. The analysis by immunofluorescence confirms these results (Fig 10). Healthy and hydrated skin are characterised by high levels of INV (with an intense green fluorescence as indicated by the circle on control untreated image). In AS, we see a drastic decrease of INV. And as expected, 3% and 5% of the new active increase strongly the Involucrin as indicated by circles on images. The new active increases INV levels in atopic skin up to normal level of healthy skin. These results confirm that the new active re-structures the cornified envelope and rebuilds the essential protective barrier.
Results
Dose-dependent beneficial effects are observed for FLG and INV when the stimulation by Th2 cytokines is combined with the presence of the new active. Remarkably, the new active allows the
restoration of: l 72% of filaggrin abundance with 5% of use l 169% of the involucrin (totally) abundance with 5% of use, meaning that the new active is able to inhibit inflammation damage recovering a normal healthy skin regarding INV levels. Additionally, the new active at 3%
reduces by 39% carbonic anhydrase 2 abundance. Therefore, the new active counteracts the deleterious effects of stimulation by Th2 cytokines. Altogether, the obtained results indicate that the new active exerts a protective
effect reducing alterations triggered by Th2 stimulation on in vitro reconstructed epidermis. The new active helps to reduce immune inflammation and restore a healthly condition in atopic skin.
Conclusion According to recent studies, 60–70% of women and 50–60% of men worldwide report they have skin that is sensitive, reactive, irritable, or intolerant.3
Sensitive skin must be
treated with the right ingredients able to repair it, protect it, moisturise it and calm unpleasant phenomena such as, itching, burning, stinging, tightness, and dryness. With its powerful active ingredients originating from the ocean’s depths, Natura- Tec is able to answer specific needs of cosmetic industry in terms of efficacy, safety and sustainability. Blue cosmetics consolidates their place in the quest to generate a sustainable future for the industry. Natura-Tec Marine OceanMist CL is the ideal ally, natural and renewable: the right solution to the specific needs of sensitive skin.
PC
References 1 Kalinin A et al. Assembly of the epidermal
cornified cell envelope, J Cell Sci 2001;114: 3069-3070
2 Cork MJ, Danby SG, Vasilopoulos Y, et al. Epidermal barrier dysfunction in atopic dermatitis. J Invest Dermatol. 2009 Aug;129(8):1892-908.
3 Farage MA. The Prevalence of Sensitive Skin. Frontiers in medicine 2019; 6: 98. doi:10.3389/fmed.2019.00098.
April 2020
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100 |
Page 101 |
Page 102 |
Page 103 |
Page 104 |
Page 105 |
Page 106 |
Page 107 |
Page 108 |
Page 109 |
Page 110 |
Page 111 |
Page 112 |
Page 113 |
Page 114 |
Page 115 |
Page 116 |
Page 117 |
Page 118 |
Page 119 |
Page 120 |
Page 121 |
Page 122 |
Page 123 |
Page 124 |
Page 125 |
Page 126 |
Page 127 |
Page 128 |
Page 129 |
Page 130 |
Page 131 |
Page 132 |
Page 133 |
Page 134 |
Page 135 |
Page 136 |
Page 137 |
Page 138 |
Page 139 |
Page 140 |
Page 141 |
Page 142 |
Page 143 |
Page 144 |
Page 145 |
Page 146 |
Page 147 |
Page 148 |
Page 149 |
Page 150 |
Page 151 |
Page 152 |
Page 153 |
Page 154 |
Page 155 |
Page 156 |
Page 157 |
Page 158 |
Page 159 |
Page 160 |
Page 161 |
Page 162 |
Page 163 |
Page 164 |
Page 165 |
Page 166 |
Page 167 |
Page 168 |
Page 169 |
Page 170 |
Page 171 |
Page 172 |
Page 173 |
Page 174 |
Page 175 |
Page 176 |
Page 177 |
Page 178 |
Page 179 |
Page 180 |
Page 181 |
Page 182 |
Page 183 |
Page 184 |
Page 185 |
Page 186 |
Page 187 |
Page 188 |
Page 189 |
Page 190 |
Page 191 |
Page 192 |
Page 193 |
Page 194 |
Page 195 |
Page 196
